- International figures, including Thomas Rachel and Penpa Tsering, are criticizing China's policies regarding Tibet, which are accused of leading to assimilation and control.
- Beijing extended legal reach to East Turkestan and entrenched assimilationist policies in Tibet while defending against Western criticism.
- Beijing's policies target ethnic minority regions, including laws that prioritize Mandarin over minority languages in Xinjiang and Tibet.
Clinical trials involving major pharmaceutical companies are being conducted in Xinjiang, raising concerns about the risks posed by the region's policies.
5 reports, 3 independent
Updated Jul 1
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 5
- Developments
- 4
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Clinical trials involving major pharmaceutical companies are being conducted in Xinjiang, raising concerns about the risks posed by the region's policies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Congressional investigation probes US firms Merck and Pfizer over clinical trials conducted in China and Xinjiang.Sub-event
A committee is investigating Eli Lilly's clinical trial operations in Xinjiang.1 source
US lawmakers are investigating trials conducted in China by AbbVie, Merck, and others.1 source
Trials in Xinjiang are facing scrutiny due to the region's policies targeting ethnic minorities.1 source
Keep exploring
Part of
Beijing's policies target ethnic minority regions, including laws that prioritize Mandarin over minority languages in Xinjiang and Tibet.Also in this story
- China implemented the new Ethnic Progress and Unity Law in Tibet.
- Beijing is enforcing data security regulations in Xinjiang, a region that includes Changji.